Skip to content

Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02797314
Acronym
DIABONE
Enrollment
60
Registered
2016-06-13
Start date
2017-03-28
Completion date
2024-03-08
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Type 2 diabetes, Bone quality, Bone biopsies, Vertebral fractures, Osteodensitometry, Trabecular Bone Score

Brief summary

Patients with type 2 diabetes have many complications in different organs. These complications are extremely frequent and severe: cardiovascular and renal disease, visual impairment, and, more recently, complications affecting bone such as fractures. Conventional methods for the evaluation of fracture risk are based on the Bone Mineral Density (BMD) or FRAX (algorithm for the prediction of osteoporotic fracture risk) are not sufficient in the context of diabetes. Several metaanalyses have shown that, paradoxically, a higher BMD in patients with type 2 diabetes compared to patients not suffering from this disease, independently of body mass index (BMI). The paradoxal increase in fracture risk, despite a high BMD has led to the hypothesis that diabetes induces a modification of the quality and not the quantity of bone. However, there is a lack of data as to bone quality in patients with type 2 diabetes as studies of bone biopsies from patients with type 2 diabetes are extremely rare. The objective of the study is to compare bone quality in patients with type 2 diabetes to that in patients who do not suffer from type 2 diabetes: evaluation of vertebral fractures by osteodensitometry, measurement of Trabecular Bone Score (TBS), and analysis of bone quality in biopsies (advanced glycation end products (AGE), contents of bone matrix and analysis of mineralization). The results will then be correlated with blood/urinary markers with the objective to determine one/several non-invasive biomarkers for bone status in diabetic patients.

Interventions

Bone biopsies

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women aged greater than 40 years * Patients requiring surgery of the lower limb * With a bone mineral density considered normal (T-score ≥ -2) * Stage 1, 2, or 3 glomerular filtration rate (\> 30 mL/min) * For diabetic patients the diagnosis will have previously established by an endocrinologist

Exclusion criteria

* Subjects treated with drugs known to interfere with bone metabolism, including steroids, anticonvulsants, diuretics, and bisphosphonates * Patients with severe renal disease (\< 30 ml/mn); previous history of caner except skin cancer; myocardial infarction; uncontrolled hypertension; untreated hyperthyroidism; hyperthyroidism; malabsorption; bone metabolism diseases; rheumatoid arthritis or collagen diseases * Pregnant or lactating woman * Contraindication to taking tetracycline hydrochloride: * Known hypersensitivity to antibiotics of the tetracycline family or any of the excipients in the medicine * Severe chronic renal failure * Chronic liver failure * Systemic lupus erythematosus * Concomitant prescription of retinoid or vitamin A (risk intracranial hypertension) * Psychiatric pathology seriously hampering understanding * Difficulty understanding oral French * Not a beneficiary of a social security scheme

Design outcomes

Primary

MeasureTime frameDescription
Bone mineral density1 month after patient inclusionBone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA)
Vertebral fractures1 month after patient inclusionPresence of vertebral fractures evaluated by Vertebral Fracture Assessment (VFA)
Trabecular Bone Score1 month after patient inclusionTrabecular bone score (TBS) is a analytical tool that performs novel grey-level texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and thereby captures information relating to trabecular microarchitecture

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026